Geode Capital Management LLC Acquires 6,839 Shares of Omeros Co. (NASDAQ:OMER)

Geode Capital Management LLC lifted its holdings in Omeros Co. (NASDAQ:OMER) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,339,251 shares of the biopharmaceutical company’s stock after purchasing an additional 6,839 shares during the quarter. Geode Capital Management LLC’s holdings in Omeros were worth $5,318,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Barclays PLC grew its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 51,873 shares in the last quarter. MML Investors Services LLC grew its stake in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. Jane Street Group LLC increased its position in shares of Omeros by 15.9% during the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 8,010 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Omeros during the 3rd quarter worth approximately $305,000. Finally, State Street Corp boosted its holdings in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Trading Up 13.9 %

Shares of OMER stock opened at $11.21 on Friday. The stock has a market cap of $649.62 million, a P/E ratio of -4.85 and a beta of 1.97. Omeros Co. has a 1 year low of $2.61 and a 1 year high of $13.60. The stock has a 50 day simple moving average of $8.32 and a 200 day simple moving average of $5.62.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price for the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Finally, D. Boral Capital initiated coverage on Omeros in a report on Monday, December 23rd. They set a “buy” rating and a $36.00 target price on the stock. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.